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ABSTRACT
The candidate human tumor suppressor gene cyclin C
is a primary target of the anti-proliferative hormone
1a,25-dihydroxyvitamin D3 [1a,25(OH)2D3], but binding
sites for the 1a,25(OH)2D3 receptor (VDR), so-called
1a,25(OH)2D3 response elements (VDREs), have not
yet been identified in the promoter of this gene. We
screened various cancer cell lines by quantitative
PCR and found that the 1a,25(OH)2D3 inducibility of
cyclin C mRNA expression, in relationship with the
24-hydroxylase (CYP24) gene, was best in MCF-7
humanbreastcancercells.Tocharacterize the molecu-
lar mechanisms, we analyzed 8.4 kb of the cyclin C
promoter by using chromatin immunoprecipitation
assays (ChIP) with antibodies against acetylated his-
tone 4, VDR and itspartner receptor, retinoid X receptor
(RXR). The histone 4 acetylation status of all 23 invest-
igated regions of the cyclin C promoter did not change
significantly in response to 1a,25(OH)2D3, but four
independent promoter regions showed a consistent,
1a,25(OH)2D3-dependent association with VDR and
RXR over a time period of 240 min. Combined
in silico/in vitro screening identified in each of these
promoter regions a VDRE and reporter gene assays
confirmedtheirfunctionality.Moreover,re-ChIPassays
monitored simultaneous association of VDR with RXR,
coactivator, mediator and RNA polymerase II proteins
on these regions. Since cyclin C protein is associated
with those mediator complexes that display transcrip-
tional repressive properties, this study contributes to
the understanding of the downregulation of a number
of secondary 1a,25(OH)2D3-responding genes.
INTRODUCTION
The biologically most active vitamin D metabolite, 1a,25-
dihydroxyvitamin D3 [1a,25(OH)2D3], is essential for
mineral homeostasis and skeletal integrity (1), but also has
important roles in the control of cell growth and differentiation
in normal and malignant tissues (2). 1a,25(OH)2D3 levels are
tightly controlled by the monooxygenase vitamin D 24-
hydroxylase (CYP24), which metabolizes the active hormone.
The CYP24 gene is also the most responsive primary
1a,25(OH)2D3 target gene and shows at the mRNA level
up to 1000-fold inducibility by the hormone (3). Most other
known primary 1a,25(OH)2D3 target genes are much less
responsive and often show an inducibility of 2-fold or less
after short-term treatment with 1a,25(OH)2D3 (4,5). One of
these genes is cyclin C (6). Cyclin C belongs to the cyclin
protein superfamily, whose members control cell cycle trans-
itions through activation of cyclin-dependent kinases (CDKs).
Human and Drosophila cyclin C proteins share a high degree
of homology (72% identity), which suggests an important role
for this gene product that is reflected in its conservation in
diverse animal species (7). Interestingly, the cyclin C–CDK8
complex was found to be associated with the RNA polymer-
ase II (Pol II) basal transcriptional machinery (8), and is con-
sidered as a functional part of those mediator protein (MED)
complexes that are involved in gene repression (9). This obser-
vation suggests a general role for cyclin C in reducing the
transcriptional activity of a cell. Another role of cyclin C, in
complex with CDK3, seems to be the regulation of the G0 to
G1 transition of the cell cycle through specific phosphorylation
of the retinoblastoma protein pRb (10). Moreover, the fact that
the cyclin C gene, being located in chromosome 6q21, is
deleted in a subset of acute lymphoblastic leukemias,
suggests its involvement in tumorigenesis (11).
The 1a,25(OH)2D3 receptor (VDR) is the only nuclear pro-
tein that binds 1a,25(OH)2D3 with high affinity (Kd = 0.1 nM).
Corepressor proteins, such as NCoR, SMRT and Alien (12),
link non-liganded, DNA-bound VDR to enzymes with histone
deacetylase activity that results in chromatin condensation
(13). This provides VDR with intrinsic repressive properties
comparable with both retinoic acid and thyroid hormone
receptors. Ligand binding to the VDR causes a conformational
change within its ligand-binding domain, which results in the
replacement of corepressors by coactivator proteins of the p160-
family, such as nuclear coactivators (NCoAs) 1, 2 and 3 (14).
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These coactivators link the ligand-activated VDR to enzymes
displaying histone acetyltransferase activity, which results
in chromatin relaxation and thereby reversing the action of
unliganded VDR (15). In a subsequent step, ligand-activated
VDR changes rapidly from interacting with the coactivators of
the p160-family to those of the MED complexes, of which
cyclin C–CDK8 (16) is a part. The MED complex acts as a
bridge from activated VDR to the basal transcriptional
machinery (17). In this way ligand-activated VDR executes
two tasks, the modification of chromatin and the regulation of
transcription.
An essential prerequisite for the direct modulation of
transcription via 1a,25(OH)2D3-triggered protein–protein
interactions is the location of at least one activated VDR
molecule close to the basal transcriptional machinery of a
1a,25(OH)2D3-responding gene. This is traditionally achieved
through the specific binding of the VDR to a 1a,25(OH)2D3
response element (VDRE) (18). The DNA-binding domain of
the VDR contacts the major groove of a double-stranded hex-
americ DNA sequence with the consensus sequence RGKTSA
(R = A or G, K = G or T, and S = C or G). In most cases the
heterodimeric partner of VDR is the retinoid X receptor (RXR),
another nuclear receptor superfamily member, which also con-
tacts DNA. Therefore, simple VDREs are often formed by a
direct repeat of two hexameric core binding motifs spaced by
3 nt (DR3-type VDRE) (19). In addition, strong DNA binding of
VDR–RXR heterodimers to two hexameric motifs arranged as a
direct repeat spaced by 4 nt (DR4-type VDRE) (20) or as an
everted repeat with nine intervening nucleotides (ER9-type
VDRE) have been described previously (21). Although indi-
vidual VDREs have been shown to be able to induce trans-
activation on their own, the presence of multiple VDREs in
any given gene promoter suggests that they may act synergist-
ically. A VDRE cluster, containing the most potent human
DR3-type VDRE known to date at its core (22), has been repor-
ted in the proximal promoter of the human CYP24 gene (23).
However, the DR3-type VDRE of the rat osteocalcin gene (24)
is the only VDR binding site that is presently understood in its
promoter context, where chromatin organization and flanking
binding sites for other transcription factors, such as Runx2 and
YY1, are taken into consideration (25).
The major protein constituents of chromatin are histones,
and the covalent modifications of lysines at their N-terminal
tails neutralize their positive charge and thus their attraction
for the negatively charged DNA is diminished (26). This influ-
ences the packaging grade of the chromatin and regulates the
access of transcription factors to their potential binding sites.
More than 10 specific modifications of histones are known, but
the acetylation of the lysine at position 8 of histone 4 correlates
strongly with the activation of chromatin on a promoter pre-
ceding the initiation of transcription (27). Therefore, in most
cases, the histones associated with active regions of promoters
have a higher degree of acetylation at certain positions than
in repressed or silent regions. To date, most studies on tran-
scriptional regulation have been concentrated on isolated pro-
moter regions or proximal promoters, where binding sites of
nuclear receptors and other transcription factors have been
localized (28).
We have previously identified the human cyclin C gene as a
primary 1a,25(OH)2D3 target (6). Since neither VDREs nor
chromatin packaging of the promoter of this gene was known,
we analyzed, in MCF-7 human breast cancer cells, 8.4 kb
of the human cyclin C promoter by using chromatin immuno-
precipitation assay (ChIP) with antibodies against acety-
lated histone 4 (AcH4), VDR and RXR. Interestingly, 1a,
25(OH)2D3 treatment did not change the acetylation status
of histone 4 on any region of the cyclin C promoter. In contrast
to this finding, up to five promoter regions showed a consist-
ent, 1a,25(OH)2D3-dependent association with VDR and
RXR over time and in four of these regions re-ChIP assays
confirmed the simultaneous association of VDR with RXR,
NCoA3, MED1 and Pol II. Furthermore, in silico screening,
gel-shift and reporter gene assays identified in each of these
four regions a DR3- or DR4-type VDRE.
MATERIALS AND METHODS
Cell culture
MCF-7 and MDA-MB453 human breast cancer cells
and LNCaP and PC-3 human prostate cancer cell were
grown in phenol red-free DMEM and RPMI, respectively,
supplemented with 5% charcoal-treated fetal bovine serum,
2 mM L-glutamine, 0.1 mg/ml streptomycin and 100 U/ml
penicillin, in a humidified 95% air/5% CO2 incubator. Before
mRNA extraction or ChIP assay, the cells were treated at a
density of 50–60% confluency for 0–360 min with 10 nM
1a,25(OH)2D3 dissolved in ethanol (kindly provided by
Dr Lise Binderup, LEO Pharma, Ballerup, Denmark) or vehi-
cle (ethanol, final concentration 0.01%).
DNA constructs
Full-length cDNAs for human VDR (29) and human RXRa
(30) were subcloned into the T7/SV40 promoter-driven pSG5
expression vector (Stratagene, La Jolla, CA). The same con-
structs were used for both T7 RNA polymerase-driven in vitro
transcription/translation of the respective cDNAs and for viral
promoter-driven overexpression in mammalian cells. Two
copies of the VDREs derived from the human cyclin C, rat
atrial natriuretic factor (ANF) and rat pit-1 gene promoters
were fused with the thymidine kinase promoter driving the
firefly luciferase reporter gene. Each fragment of the human
cyclin C promoter [from 2176 to 1786 relative to transcrip-
tion start site (TSS)] and the human CYP24 promoter (from
414 to 173) were cloned by PCR from human genomic
DNA and also fused with the luciferase reporter gene. All
constructs were verified by sequencing. The core sequences
of the cyclin C VDREs are indicated in Figure 4A and the core
sequences of the rat ANF and rat pit-1 REs were AGAGGT-
CATGAAGGACA (31) and GAAGTTCATGAGAGTTCA
(32), respectively.
RNA extraction and real-time quantitative PCR
Total RNA and mRNA were extracted using Tri-reagent
(Sigma-Aldrich, St Louis, MO) and Oligotex mini mRNA
kit (Qiagen, Hilden, Germany), respectively. An aliquot of
100 ng of mRNA was used as a template in cDNA synthesis
reaction using 100 pmol of oligodT18 primer in the presence
of reverse transcriptase (Fermentas, Vilnius, Lithuania). The
reaction was performed for 1 h at 37C. Real-time quantitative
PCR was performed in an IQ-cycler (Bio-Rad, Hercules, CA)
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by using the dye SybrGreen (Molecular Probes, Leiden,
The Netherlands). In PCRs, 3 mM MgCl2 was used for all
primers. The PCR cycling conditions used were: 40 cycles of
30 s at 95C, 30 s at 58C (62C for CYP24) and 40 s at 72C.
Fold inductions were calculated using the formula 2(DDCt),
where DDCt is the DCt
1a‚ 25 OHð Þ2D3½ DCt Ethanolð Þ, DCt is
Ct(cyclin C or CYP24)  Ct(ARP0) and Ct is the cycle at which
the threshold is crossed. The gene-specific primer pairs (and
product sizes) for the gene analyzed here were as follows:
cyclin C gene forward 50-TGCCTACATGTAGCCTGTGT-
30 and reverse 50-GCTGTAGCTAGAGTTCTGAC-30
(242 bp), CYP24 gene forward 50-CAAACCGTGGAAGGCC-
TATC-30 and reverse 50-AGTCTTCCCCTTCCAGGATCA-30
(70 bp) (33), acidic riboprotein P0 (ARP0, also known as
36B4) control gene forward 50-AGATGCAGCAGATCCG-
CAT-30 and reverse 50-GTGGTGATACCTAAAGCCTG-30
(318 bp). PCR product quality was monitored using post-
PCR melt curve analysis.
ChIP assays
Nuclear proteins were cross-linked to DNA by adding
formaldehyde for 15 min directly to the medium to a final
concentration of 1%. Cross-linking was stopped by adding gly-
cine to a final concentration of 0.125 M and incubating at room
temperature for 5 min on a rocking platform. The medium was
removed and the cells were washed twice with ice-cold PBS
(140 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4 and 8.1 mM
Na2HPO42H2O). The cells were collected by scraping in ice-
cold PBS supplemented with a protease inhibitor cocktail
(Roche Diagnostics, Mannheim, Germany). After centrifuga-
tion, the cell pellets were resuspended in lysis buffer (1% SDS,
10 mM EDTA, protease inhibitors and 50 mM Tris–HCl,
pH 8.1) and the lysates were sonicated to obtain DNA frag-
ments of 300–1000 bp in length. Cellular debris was removed
by centrifugation and the lysates were diluted 1:10 in ChIP
dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM
EDTA, 16.7 mM NaCl, protease inhibitors and 16.7 mM
Tris–HCl, pH 8.1). Non-specific background was removed
by incubating the chromatin resuspension with a salmon
sperm DNA/protein A agarose slurry (Upstate Biotechnology,
Lake Placid, NY) for 30 min at 4C with agitation. The samples
were centrifuged and the recovered chromatin solutions were
incubated with 5 ml of indicated antibodies overnight at 4C
with rotation. The antibody against AcH4 was from Upstate
Biotechnology (06-866), whereas antibodies against VDR (sc-
1008), RXRa (sc-553), NCoA3/RAC3 (sc-7216), MED1/
TRAP220 (sc-5334) and phosphorylated Pol II (sc-13583)
were obtained from Santa Cruz Biotechnologies (Heidelberg,
Germany). The immuno-complexes were collected with 60 ml
of protein A agarose slurry (Upstate Biotechnology) for 2 h at
4C with rotation. The beads were pelleted by centrifugation for
1 min at 4C at 100 g and washed sequentially for 5 min by
rotation with 1 ml of the following buffers: low-salt wash buffer
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl and
20 mM Tris–HCl, pH 8.1), high-salt wash buffer (0.1% SDS,
1% Triton X-100, 2 mM EDTA, 500 mM NaCl and 20 mM
Tris–HCl, pH 8.1) and LiCl wash buffer (0.25 mM LiCl, 1%
Nonidet P-40, 1% sodium deoxycholate, 1 mM EDTA and
10 mM Tris–HCl, pH 8.1). Finally, the beads were washed
twice with 1 ml TE buffer (1 mM EDTA and 10 mM
Tris–HCl, pH 8.0). For re-ChIP, the immuno-complexes
were eluted by adding 200 ml re-ChIP elution buffer (10 mM
DTT) for 30 min at room temperature with rotation, the super-
natant was diluted 1:40 in ChIP dilution buffer and the antibody
against the second protein of interest was added, the new
immuno-complexes were allowed to form by incubating over-
night at 4C on a rocking platform, the immuno-complexes
were collected by incubating with 60 ml protein A agarose
slurry for 2 h at 4C on a rocking platform and finally washed
as indicated above. In both cases, the immuno-complexes were
then eluted by adding 250 ml elution buffer (1% SDS and
100 mM NaHCO3) and incubated for 15 min at room temper-
ature with rotation. After centrifugation, the supernatant was
collected and the elution was repeated. The supernatants were
combined and the cross-linking was reversed by adding NaCl to
a final concentration of 200 mM and incubated overnight at
65C. The remaining proteins were digested by adding pro-
teinase K (final concentration 40mg/ml) and incubated for 1 h at
45C. The DNA was recovered by phenol/chloroform/isoamyl
alcohol (25:24:1) extractions and precipitated with 0.1 vol of
3 M sodium acetate, pH 5.2 and 2 vol of ethanol using glycogen
as a carrier.
PCR of chromatin templates
For a complete coverage of the first 8.4 kb of the human cyclin C
promoter, 23 primer pairs were designed (Table 1), optimized
and controlled by running PCRs with 25 ng genomic DNA
(input) as a template. When running immuno-precipitated
DNA (output) as a template, 10 ng was used in the optimized
conditions for each PCR with the following profile: preincuba-
tion for 5 min at 94C, 40 cycles of 30 s denaturation at 95C,
30 s annealing at primer-specific temperature (see Table 1) and
30 s elongation at 72C, with one final incubation for 10 min at
72C. The PCR products were separated by electrophoresis
through 2.0% agarose gels supplemented with 0.5 mg/ml eth-
idium bromide and quantified using a FLA-3000 reader (Fuji,
Tokyo, Japan) with Image Gauge software (Fuji).
Gel-shift analysis
In vitro translated VDR and RXR proteins were generated by
coupled in vitro transcription/translation using their respective
pSG5-based full-length cDNA expression constructs (29) and
rabbit reticulocyte lysate as recommended by the supplier
(Promega, Madison, WI). Protein batches were quantified by
test translation in the presence of [35S]methionine. The specific
concentration of the receptor proteins was adjusted to 	4 ng/ml
(10 ng corresponds to 	0.2 pmol) after taking the individual
number of methionine residues per protein into account. Gel-
shift assayswere performed with 10ngof theappropriate invitro
translated proteins. The proteins were incubated for 15 min in a
total volume of 20 ml binding buffer (150 mM KCl, 1 mM DTT,
0.2 mg/ml poly(dI–dC), 5% glycerol and 10 mM HEPES, pH
7.9). Constant amounts (1 ng) of 32P-labeled double-stranded
oligonucleotides (50 000 c.p.m.) corresponding to one copy of a
dimeric RE were then added and incubation was continued for
20 min at room temperature. Protein–DNA complexes were
resolved by electrophoresis through 8% non-denaturing poly-
acrylamide gels in 0.5·TBE (45 mM Tris, 45 mM boric acid and
1 mM EDTA, pH 8.3) and quantified on a FLA-3000 reader
using Image Gauge software.
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Transfection and luciferase reporter gene assays
MCF-7 cells were seeded into six-well plates (105 cells/ml)
and grown overnight in phenol red-free DMEM supplemented
with 5% charcoal-stripped fetal bovine serum. Plasmid DNA
containing liposomes were formed by incubating a reporter
plasmid and expression vector for human VDR (each 1 mg)
with 10 mg N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethyl-
ammonium methylsulfate (DOTAP) (Roth, Karlsruhe,
Germany) for 15 min at room temperature in a total volume
of 100 ml. After dilution with 900 ml phenol red-free DMEM,
the liposomes were added to the cells. Phenol red-free DMEM
supplemented with 500 ml of 15% charcoal-stripped fetal
bovine serum was added 4 h after transfection. At this time,
100 nM 1a,25(OH)2D3 or solvent was also added. The cells
were lysed 16 h after the onset of stimulation using the reporter
gene lysis buffer (Roche Diagnostics) and the constant light
signal luciferase reporter gene assay was performed according
to the supplier’s recommendation (Canberra-Packard,
Groningen, The Netherlands). The luciferase activities were
normalized with respect to protein concentration and induction
factors were calculated as the ratio of luciferase activity
of ligand-stimulated cells to that of solvent controls.
RESULTS
Basal expression of cyclin C and CYP24 in different
cancer cell lines
The basal expression levels of the two primary 1a,25(OH)2D3
target genes, cyclin C and CYP24, were monitored by real-time
Table 1. Genomic PCR primer sequences and their location within the human cyclin C and CYP24 promoters
Region nos Annealing temperature (C) Location Primer sequences
1 60 +97 to 220 50-CTGCCATGGAACACAGCTTG-30
50-CGAGCTCTCGTGAACACTAG-30
2 58 117 to 617 50-ATCGACAAAAGTTCCGGCCC-30
50-GAGAATCGCTTGAACTCCTG-30
3 60 329 to 1196 50-CGAAGTGGCTCAGATACGGG-30
50-GCAATGAGCCTAGATAGCGC-30
4 60 1176 to 1842 50-GCGCTATCTAGGCTCATTGC-30
50-ACACCCTAATTGGTCTCCAC-30
5 60 1385 to 1842 50-CGGCCGCGATCTTAATGGAG-30
50-ACACCCTAATTGGTCTCCAC-30
6 60 1786 to 2176 50-CAGTCAGCATCTGAGGCAAC-30
50-GCCACCACACTCCGCTAATT-30
7 60 2118 to 2453 50-GGGACTTTATGGGAGTGACG-30
50-GCCAACATGGTGAAACCCTG-30
8 60 2433 to 2885 50-CCTCCCAAGTAGCTAGGATC-30
50-CGTCACTCCCATAAAGTCCC-30
9 60 2783 to 3456 50-GGCCTGGAGTTTCTTAAGGTAG-30
50-CATGGCCAGCATGGTGAAAC-30
10 58 3169 to 3456 50-GGCCTGGAGTTTCTTAAGGTAG-30
50-GAGACCATCCTGGCTAACAC-30
11 60 3437 to 3867 50-ACCTTAAGAAACTCCAGGCC-30
50-GGCTGAGGTGGGTGGATTAA-30
12 58 3801 to 4197 50-GTGGAAGCAGAAACCAGGTC-30
50-GGGGTTTCACCATGTTGGTC-30
13 58 4177 to 4758 50-GACCTGGTTTCTGCTTCCAC-30
50-GCTTGAGATGATGGATACCC-30
14 60 4509 to 4988 50-TTTCAGACCTCACTACCCAC-30
50-ATTCCAGGTATTCTTGCCGC-30
15 58 4924 to 5374 50-GGAGCTAGAAGGTTAGTGGC-30
50-GAGAGCCTCTCTCTGTTATC-30
16 58 5217 to 5746 50-GTAGTCATCCCCTGTACCTC-30
50-AGCCTCAAAGGGCCATGAAG-30
17 60 5628 to 6039 50-TTCGTGCAAGGTTGCTGTGG-30
50-GGCCTCTGCCTTCATGAATG-30
18 60 5960 to 6354 50-AAGACGGGGCCAAACTCATC-30
50-CTATGTATCAGGCACTGCTC-30
19 58 6286 to 6788 50-GGTAAGTCATAGGGTTGTGG-30
50-GGCCATTTCTTGATCCTGGG-30
20 58 6728 to 7202 50-GAGCCAGATCTCTTCAATCC-30
50-CCAGAGTAGCTATCTTCAGC-30
21 58 7082 to 7522 50-TGTGCCACAGCAAGATGGTG-30
50-CCCTCTGTCCTCAGAGTTTC-30
22 60 7464 to 7877 50-GGTTCATCATGGAGTGTGGG-30
50-CATCCAGACTCCAGACACAG-30
23 58 7825 to 8383 50-AGTCCCCACAGCATAACAGG-30
50-CTTAAGTCTGTGGGCCAGAG-30
1CYP24 66 64 to 480 50-GTCCAGGCTGGGGGTATCTG-30
50-CCACTCCGCCCTCCTCTGCG-30
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quantitative PCR in relationship with the control gene ARP0 in
MCF-7 and MDA-MB453 human breast cancer cells and in
LNCaP and PC-3 human prostate cancer cells (Figure 1A).
MCF-7 and LNCaP are less agressive estrogen- and
testosterone-dependent cell lines, respectively, while MDA-
MB453 and PC-3 are sex-hormone-insensitive cells. The basal
expression of the cyclin C gene was found to be comparable
in MCF-7 and LNCaP cells and was 	30 000-fold higher than
that of the basal mRNA expression of the CYP24 gene. The
expression of the cyclin C gene was nearly 10-fold higher in
MDA-MB453 cells than in MCF-7 and LNCaP cells, while the
CYP24 mRNA level was <3-fold elevated in MDA-MB453
cells compared with the two other cell lines. This results in a
nearly 100 000-fold difference in the basal mRNA expression
of cyclin C and CYP24 in these cells. Finally, in PC-3 cells the
cyclin C mRNA level was found to be 3-fold higher than that in
both MCF-7 and LNCaP cells, but the CYP24 gene expression
was 10-fold elevated. This means that the two genes differ in
their expression only by a factor of 10 000-fold in this cell line.
1a,25(OH)2D3 inducibility of cyclin C and CYP24 in
different cancer cell lines
All four cell lines were treated for 2 h with 10 nM
1a,25(OH)2D3 and the fold change of normalized cyclin C
and CYP24 mRNA was measured in relationship with the
solvent control (Figure 1B). After this short-term stimulation
the cyclin C mRNA level was found to be 1.8-fold upregulated
in MCF-7 cells, 1.6-fold in LNCaP cells, 1.2-fold in MDA-
MB453 cells and slightly reduced in PC-3 cells. In compar-
ison, CYP24 gene expression was increased to 3.9-fold in
MCF-7 cells, 6.1-fold in LNCaP cells, 3.3-fold in MDA-
MB453 cells and 10.8-fold in PC-3 cells within the same
time period. This means that MCF-7 cells showed not only
the highest absolute induction of the cyclin C gene, but also
monitor, in comparison with the CYP24 gene, the highest
relative induction. Since cyclin C mRNA molecules are
more abundant (reflected in the high-basal level of the
mRNA relative to the ARP0 control gene), we estimate that
MCF-7 cells synthesized within the 2 h stimulation period
	7600-fold more cyclin C mRNA molecules than CYP24
mRNA molecules. A 6 h time course of cyclin C expression
in MCF-7 cells (Figure 1C) suggests that the upregulation of
the gene was very transient and showed a maximum after 2 h
stimulation. This is in contrast to the CYP24 gene, which
showed a steady increase in mRNA amount up to >400-fold
induction after 6 h stimulation (data not shown). Taken
together, the real-time quantitative PCR results suggest that
MCF-7 cells are most suited for investigations of the
1a,25(OH)2D3-induction of the human cyclin C promoter.
Whole cyclin C promoter screening for histone 4
acetylation levels
We hypothesized that a transient upregulation of the
cyclin C gene should result in dynamic changes in the chro-
matin activation state on a wider region of the promoter of the
gene in response to 1a,25(OH)2D3 stimulation. In order to test
this hypothesis, we designed 23 overlapping primer pairs that
cover evenly the first 8.4 kb of chromosomal DNA upstream of
the TSS of the cyclin C gene (Table 1). As a reference, a primer
pair covering the proximal promoter of the CYP24 gene, con-
taining the known VDRE cluster (34), was used. To minimize
the number of primers in repetitive sequences, we employed
the web-based CENSOR server screening service (35) to
identify repetitive sequences in the promoter sequence. We
determined that the repetitive sequence content of this
segment of human chromosome 6 is 	46%. The remaining
54% unique sequence was used to design the overlapping
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Figure 1. Comparison of cyclin C and CYP24 mRNA expression. Real-time
quantitative PCR was used to determine the ratio of the basal levels of cyclin C
and CYP24 mRNA relative to the control gene ARP0 in MCF-7 and MDA-
MB453 human breast cancer and in LNCaP and PC-3 human prostate cancer
cells (A). A logarithmic scale is employed on the y-axis to better present the
data. (B) In the same four cell lines, the induction of cyclin C and CYP24 mRNA
after 2 h treatment with 10 nM 1a,25(OH)2D3 was measured. (C) The time
course of cyclin C mRNA expression in response to 10 nM 1a,25(OH)2D3 was
determined in MCF-7 cells. Data points (A and C) and columns (B) indicate the
means of at least three independent cell treatments and the bars represent the
standard error of mean. The standard deviations in (A) are too small to be visible
in relationship with the data points.
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PCR primer pairs. Chromatin was extracted from MCF-7 cells
that were grown overnight in the presence of 5% charcoal-
treated fetal bovine serum, stimulated for 0, 30, 60, 120 and
180 min with 10 nM 1a,25(OH)2D3 and then cross-linked for
15 min in the presence of formaldehyde. ChIP assays were
performed using an antibody against AcH4 and representative
agarose gels of the PCR products from all treatment times are
shown in Figure 2A. Comparable detection sensitivity for the
23 different cyclin C promoter regions and the proximal
CYP24 promoter was demonstrated by the representative
PCR products that were obtained using DNA liberated from
the recovered chromatin by reverse cross-linking (input lane).
PCR products obtained with AcH4-enriched chromatin visu-
alized the acetylation status of each of the 23 regions of the
cyclin C promoter in comparison with that of the proximal
CYP24 promoter. Cell treatment, chromatin extraction and
PCR were performed at least six times and the basal histone
4 acetylation level was quantified in relationship with their
respective chromatin input (Figure 2B). Interestingly, while
the proximal promoter of the CYP24 gene showed a low acet-
ylation level, all 23 regions of the cyclin C promoter displayed
significantly more association with AcH4. The latter was high-
est at the TSS and within the first 617 bp of the promoter
(regions 1 and 2) and lowest at promoter regions 3, 10 and 11.
However, the histone 4 acetylation level of all regions of the
cyclin C promoter did not vary more than by a factor of 2.
Moreover, for each of the 23 regions of the cyclin C promoter
the histone 4 acetylation level did not change significantly in
response to 1a,25(OH)2D3 (Figure 2A). In contrast, AcH4
association with the proximal CYP24 promoter showed a
steady increase after 60 min ligand stimulation. In summary,
the ChIP assay results demonstrate that the histone 4 acetyla-
tion level of the cyclin C promoter is, in contrast to that of the
CYP24 promoter, not suited to monitor regulatory effects of
1a,25(OH)2D3. However, the high-basal levels reflect the fact
that the cyclin C gene is highly transcribed in the absence of
the hormone (Figure 1A).
VDR location on the cyclin C promoter
We next screened the whole cyclin C promoter for regions
that precipitated with anti-VDR antibodies (Figure 3A). Over
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Figure 2. Chromatin activity of the human cyclin C promoter. Chromatin was extracted from MCF-7 cells that had been treated for indicated time periods with 10 nM
1a,25(OH)2D3. ChIP assays using an antibody against AcH4 were performed. The histone 4 acetylation states of 23 overlapping regions representing the first 8.4 kb
of the human cyclin C promoter was monitored for the five treatment times in comparison with the activity of the proximal promoter of the CYP24 gene (promoter
region 1). (A) Representative agarose gels are shown. (B) The basal activity of the promoter regions (time point 0 min) was determined by quantifying the ethidium
bromide-stained PCR products on a FLA-3000 reader in relationship with the chromatin input. Columns indicate the means of at least six independent cell treatments
and the bars represent standard error of mean.
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a stimulation period of 240 min with 10 nM 1a,25(OH)2D3,
VDR association centered at promoter regions 1, 6, 16, 20 and
23. These regions were separated by regions 2–4, 8–14, 18 and
22, which showed no or only very faint association with VDR.
Since a portion of the chromatin template fragments were
significantly larger than the amplified PCR products, the sig-
nals obtained at regions 5 and 7, 15 and 17, and 19 and 21 are
interpreted as flanking effects. Promoter regions 1, 6, 20 and
23 as well as the proximal CYP24 promoter showed a signi-
ficant increase in VDR association over time with a maximum
between 60 and 180 min. In contrast, promoter region 16
displayed constitutive association with VDR, which was not
significantly increased in response to 1a,25(OH)2D3. Taken
together, the ChIP assay results indicate that, in contrast to
histone 4 acetylation, VDR association is better suited to mon-
itor 1a,25(OH)2D3-dependent changes of the cyclin C and
CYP24 promoters. These results also indicate that up to five
regions within the cyclin C promoter are nucleation points for
activated VDR.
RXR location on the cyclin C promoter
We next screened the whole cyclin C promoter with ChIP
assays using an antibody against the VDR partner receptor
RXR over a stimulation period of 240 min with 10 nM
1a,25(OH)2D3 to identify potential VDR–RXR heterodimer
binding regions (Figure 3B). From the results, it was found that
the pattern of RXR location on the cyclin C promoter was
nearly identical to the pattern obtained with the anti-VDR
antibody (Figure 3A). RXR association centered at promoter
regions 1, 6, 16, 19 and 23 that were isolated from each other
by the non-associating regions 2–4, 8–14, 17, 21 and 22.
Signals observed at regions 5, 7, 15 and 18 might be explained
by being regions that flank positive regions. The only differ-
ence between the RXR and VDR association patterns was
observed at regions 18–21, where the RXR patterns suggest
region 19 as the center while the VDR pattern suggested region
20. In general, RXR binding to the different regions of the
cyclin C promoter showed to be rather constitutive and no
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Figure 3. Ligand-modulated VDR and RXR binding to the human cyclin C promoter. Chromatin was extracted from MCF-7 cells that had been treated for indicated
time periods with 10 nM 1a,25(OH)2D3. ChIP assays using an antibody against VDR (A) and RXR (B) were performed. The VDR and RXR association of the 23
regions of the human cyclin C promoter was monitored for the six treatment times in comparison with that of the proximal promoter of the CYP24 gene (promoter
region 1). Representative agarose gels are shown.
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significant effects of 1a,25(OH)2D3 on the association level of
RXR with these regions could be detected. In contrast, on the
proximal CYP24 promoter RXR binding displayed a clear
maximum between 60 and 120 min. In summary, RXR
location fits almost perfectly VDR location and suggests
that promoter regions 1, 6, 16, 19/20 and 23 are able to
bind VDR–RXR heterodimers.
Identification of VDREs on cyclin C promoter
The ChIP assays with anti-VDR and anti-RXR antibodies
(Figure 3) suggest that the human cyclin C promoter may
contain up to five VDREs. In order to challenge this prediction,
we performed in silico screening of the first 8.4 kb of the cyclin
C promoter for DR3-, DR4- and ER9-type response elements
(REs) with the consensus sequence RGKTSA allowing for
one mismatch per hexameric sequence. Applying this rule
we found nine DR3-type REs, eight DR4-type REs and two
ER9-type REs. From these 19 REs, 6 were found in the area of
the VDR–RXR binding promoter regions 6, 16, 19/20 and 23.
These were two DR3-type REs (RE7 and RE8 in regions 20
and 23, respectively) and four DR4-type REs (RE2, RE5, RE6
and RE9 in regions 6, 16, 19 and 23, respectively) (Figure 4A).
From the remaining 13 putative VDREs outside of these 5
promoter regions, only the sequences of the 2 DR3-type REs
1 and 3 (in regions 3 and 11, respectively) and 1 DR4-type RE4
(close to region 11) were found interesting enough for further
investigations. Surprisingly, no high-quality putative RE was
found in region 1 and no promising ER9-type RE in the whole
promoter area. Although RE8 and RE9 in region 23 form a
cluster, the constituting DR3- and DR4-type REs were tested
individually to examine their relative contribution to potential
VDR–RXR binding.
On all of the nine putative VDREs, gel-shift assays were
performed with in vitro translated VDR and RXR protein,
either alone or in combination (Figure 4B), under conditions
identical to our earlier DR3-type VDRE comparative study
(22). RE2 bound 2.87-fold more effective VDR–RXR het-
erodimers than the reference DR3-type VDRE of the proximal
human CYP24 promoter (23), while the relative binding of
VDR–RXR to RE5, RE7 and RE8 was only 4, 27 and 16%,
respectively, of the reference element. Neither VDR nor RXR
homodimers was observed on any of the 10 tested REs. The
binding strength of the DR4-type RE2 in region 6 belongs to
the strongest known VDRE class (i.e. type I), while the DR4-
type RE5 in region 16, the DR3-type RE7 in region 20 and the
DR3-type RE8 in region 23 are class II-type VDREs (22). In
contrast, the isolated REs 1, 3, 4, 6 and 9 did not show any
binding of VDR–RXR heterodimers. This suggests that the
additional 10, more degenerate, putative REs outside of
regions 3, 6, 11, 16, 19/20 and 23 may not allow any
in vitro binding of VDR–RXR heterodimers. Taken together,
our in silico/in vitro scanning for functional VDREs in the
cyclin C promoter (summarized in Figure 4C) indicated that
from 19 putative DNA-binding sites of the VDR only REs 2, 5,
7 and 8 in regions 6, 16, 20 and 23, respectively, showed
significant VDR–RXR heterodimer binding. Since these
four regions also show ligand-dependent association with
VDR in ChIP assays, we conclude that the VDREs are
responsible for the VDR and RXR association.
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Functionality of cyclin C VDREs in MCF-7 cells
In order to test the functionality of the REs 2, 5, 7 and 8, two
copies of each of these REs were fused with the thymidine
kinase promoter driving the firefly luciferase reporter gene,
transfected into MCF-7 cells and stimulated for 16 h with
100 nM 1a,25(OH)2D3 (Figure 5A). Two copies of the rat
ANF DR3-type VDRE and the rat pit-1 DR4-type RE, which
are the best REs in their categories (22), mediated a 17.4- and
26.2-fold induction of reporter gene activity, respectively. The
VDREs of the cyclin C promoter did not show that high a
response to ligand treatment, but the 18.8-, 3.0-, 8.3- and
5.6-fold inductions after ligand stimulation for REs 2, 5, 7
and 8, respectively, are still representing 72, 17, 48 and 15%
of the inducibility of their respective DR4- and DR3-type
reference VDREs.
The functionality of RE2 in its natural promoter context was
tested by analyzing the inducibility of a 390 bp fragment of the
human cyclin C promoter (from 2176 to 1786) in MCF-7
cells measured by luciferase reporter gene assays. We obtained
a 8.4-fold induction of luciferase activity after stimulation
with 100 nM 1a,25(OH)2D3 (Figure 5B). This is very much
comparable with the 8.9-fold induction of a reference pro-
moter fragment of the human CYP24 promoter containing
the DR3-type VDRE used in Figure 4B. In summary, reporter
gene assays confirmed the functionality of the DR3- and DR4-
type VDREs 2, 5, 7 and 8 in promoter regions 6, 16, 20 and 23,
respectively, and the most potent VDRE, RE2, of the cyclin C
promoter showed in its natural promoter context the same
ligand inducibility as the DR3-type VDRE of the human
CYP24 promoter.
Co-localization of VDR and RXR on cyclin C
promoter regions
An additional test for the functionality of the VDREs in the
chromatin context of MCF-7 cells was performed by re-ChIP
assay (Figure 6). In this assay, first the anti-VDR antibody and
then antibodies against RXR, NCoA3, MED1 or phospho-
rylated Pol II were used for immuno-precipitation, so that
the enriched chromatin templates should have been associated
with both VDR and its partner proteins at the same time. From
this double-fractionated chromatin template, the cyclin C
promoter regions 6, 16, 20 and 23 were amplified, but not
the negative control region 11. The association of VDR
with its partner proteins showed an individual profile on the
cyclin C promoter regions 6, 16, 20 and 23 as well as on the
proximal CYP24 promoter in their relative strength, but most
of them showed their maximum at the time point 60 min after
ligand treatment. In summary, re-ChIP assays confirmed the
simultaneous association of VDR with RXR, NCoA3, MED1
or phosphorylated Pol II on all four 1a,25(OH)2D3-responsive
cyclin C promoter regions.
DISCUSSION
This study describes a deeper understanding of the regulation
of the cyclin C gene by 1a,25(OH)2D3. The cyclin C gene is
an interesting 1a,25(OH)2D3-responding gene, since its func-
tion is not linked to the classical endocrine functions of
1a,25(OH)2D3, such as the regulation of calcium homeostasis
and bone mineralization, but to the regulation of cellular
A B
0
2
4
6
8
10
12
R
el
at
iv
e 
lu
ci
fe
ra
se
 a
ct
iv
ity
(R
E2
hc
yc
C)
2
(R
E5
hc
yc
C)
2
(R
E7
hc
yc
C)
2
(R
E8
hc
yc
C)
2
(D
R3
rA
N
F)
2
(D
R4
rP
it-
1) 2
em
pt
y 
ve
ct
or
Cy
cl
in
 C
 
(-2
17
6 
to
 -1
78
6)
CY
P2
4 
 
(-4
14
 to
 -1
73
)
18.8 x
3.0 x
8.3 x
5.6 x
17.4 x
26.2 x1α,25(OH)2D3
solvent
0
100
200
300
400
R
el
at
iv
e 
lu
ci
fe
ra
se
 a
ct
iv
ity
8.4 x 8.9 x
Figure 5. Functionality of VDREs. Reporter gene assays were performed with extracts from MCF-7 cells that were transiently transfected with a luciferase reporter
construct containing two copies of RE2, RE5, RE7, RE8, the DR3-type VDRE of the rat ANF gene and the DR4-type RE of the rat pit-1 gene (A) or 390 bp fragment of
the human cyclin C promoter containing RE2 and a comparable fragment of the human CYP24 promoter including the DR3-type VDRE (B) and an expression vector
for human VDR. Cells were treated for 16 h with either solvent or 100 nM 1a,25(OH)2D3. Relative luciferase activity is shown and fold inductions are indicated above
the columns. Columns represent means of at least three experiments and bars indicate standard deviations.
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growth. Being identified as a member of the cyclin family, the
regulation of cyclin C by 1a,25(OH)2D3 should provide a
more detailed understanding of the mechanisms of how
1a,25(OH)2D3 regulates cellular functions, such as prolifera-
tion, differentiation and apoptosis. However, despite some
function in the G0–G1 transition (10), the main function of
cyclin C protein seems to be acting as a component of MED
complexes. This suggests that cyclin C regulates the general
transcription rate rather than the cell cycle. Therefore, it is
possible that the effects that cyclin C has on the cell cycle are
secondary in nature and derive from an effect on the build up of
other products involved more intimately in cell cycle regula-
tion. Interestingly, cyclin C has been reported to be contained
only in those MED complexes that have a transcriptionally
repressive function (16). The cyclin C–CDK8 complex phos-
phorylates the C-terminal domain of Pol II (8) and the basal
transcription factor TFIIH (36) and both of the phosphoryla-
tions terminate transcription. Nevertheless, the impact of a
gene that represses mRNA transcription in general, is at
least as high as that of a gene that influences the cell cycle.
In the context of both functions the transient expression of the
cyclin C is important and makes sense. Cyclin C mRNA accu-
mulates periodically during the cell cycle, peaking in G1 (37).
Moreover, cyclin C protein was shown to have a half-life of
4 h (38) and in this study we have shown that the increase in
cyclin C mRNA expression in response to 1a,25(OH)2D3 is
very transient (Figure 1C). In contrast, for an enzyme, such as
the monooxygenase CYP24, it is important to stay active for a
longer time period and its expression should be independent of
the cell cycle.
The reference gene of this study, CYP24, is the most
responsive primary VDR target gene and is expressed in
numerous tissues. It has a special role in 1a,25(OH)2D3 sig-
naling, because its protein product leads to the degradation of
1a,25(OH)2D3 and, therefore, the eventual extinction of the
transcriptional signal. VDR–RXR heterodimers are the central
transcription factors on the CYP24 promoter, so that it is not
surprising that the basal expression of the gene in the absense
of an activating signal for VDR–RXR heterodimers is very
low (Figure 1A). In contrast, the basal expression of the
cyclin C gene is 10 000–100 000-fold higher than that of the
CYP24 gene (Figure 1A), suggesting that transcription factors
other than VDR–RXR heterodimers contribute to the activity
of the gene. An in silico screening for putative transcription
factor binding sites highlighted each two nuclear factor kB
(NFkB) and AP-1 binding sites located between positions
5800 and 6800 of the human cylin C promoter. Interest-
ingly, cyclin C was listed recently as a NFkB responding gene
(39). The high-basal activity of the cyclin C gene is also
demonstrated by the overall high level of histone 4 acetylation
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throughout the whole 8.4 kb of its promoter (Figure 2). More-
over, the fact, that a treatment with 1a,25(OH)2D3 is visible on
the level of histone 4 acetylation of the proximal CYP24 pro-
moter but not on the whole cyclin C promoter (Figure 2A),
confirms the dominating role of VDR–RXR heterodimers for
the CYP24 gene regulation and relativizes their impact for the
cyclin C gene. However, since the behavior of most primary
1a,25(OH)2D3-responding genes resembles more than that of
the cyclin C gene, with a modulation of the mRNA amount by
a factor of only 1.5–2.0, the strong response of the CYP24 gene
has to be considered as an exception.
A number of nuclear receptor target gene promoters, such as
the CYP24 or the estrogen-induced pS2 gene (28), appear to
have one dominating RE and the analysis of the chromatin
status has mostly concentrated on these core promoter regions.
In this study, we also found one strong VDRE (RE2) within the
cyclin C promoter, which in addition is the RE closest to the
TSS (position 2100). This VDRE may be considered as
sufficient for understanding the full response of the cyclin C
gene to 1a,25(OH)2D3. However, in addition to promoter
region 6, in which RE2 is located, ChIP screening with
anti-VDR and anti-RXR antibodies consistently identified
four additional VDR–RXR associating regions, three of
which contain classical VDREs. The ChIP signal obtained
for region 1, which contains the TSS may be due to the inter-
action of the VDR–RXR bound to the VDREs at promoter
regions 6, 16, 20 and 23 via traditional ‘DNA looping model’
(40), i.e. a false positive result.
Accepting that the cyclin C promoter has up to four func-
tional VDREs, raises the question of their purpose. Although
the in vitro DNA-binding affinity of VDR–RXR heterodimers
to REs 5, 7 and 8 and their inducibility in MCF-7 cells was
clearly lower than that of RE2, on chromatin level all four
VDRE-containing promoter regions show equal association
strength with VDR or RXR (Figure 3). Other transcription
factors that bind in the vicinity stabilize a VDR–RXR hetero-
dimer to a VDRE, which is physically weak under the stringent
in vitro binding conditions. Such a phenomenon has already
been described to explain the binding of VDR–RXR heterodi-
mers to the proximal VDRE of the rat CYP24 gene promoter
(41). Alternatively, the four distinct REs could come together
simultaneously and work co-operatively as has been already
observed with the RE clusters of other nuclear receptor target
genes, such as CYP2B6 and CYP3A4 (42). Thus, REs can act
synergistically in the activation of the respective genes, which
could also be the case for the cyclin C promoter.
The strong DR4-type VDRE at position 2100 relative to
the TSS, RE2, belongs to the most potent known VDR–RXR
heterodimer binding sites. Under the same stringent evalution
criteria as applied in a comparative study of all known VDREs
(22), the VDRE shows 25% of the VDR–RXR heterodimer
binding strength of the DR4-type RE of the rat pit-1 promoter
(32) and even 72% of its inducibility in MCF-7 cells. The latter
RE is formed by two perfect hexameric half-site with optim-
ized 50-flanking sequences (43) and has served as a reference
in a number of comparative nuclear receptor studies
(22,43,44), but its general physiological impact can be ques-
tioned, since it is located in a chromatin region that is only
active during a short time in embryonic development. The
DR4-type VDRE of the human cyclin C promoter is nearly
3-fold more potent compared with the DR3-type VDRE of the
human CYP24 proximal promoter (Figure 4B), which is pres-
ently the best human VDRE (22). RE2 of the human cyclin C
promoter is also comparable in its strength with the DR3-type
VDREs of the rat ANF gene (31) or the mouse osteopontin
gene (45). This makes the cyclin C VDRE the most potent
known human VDRE. Therefore, it is likely that in future it
will serve as a reference to a number of studies on novel
VDREs. Moreover, the examples of the VDREs of the
cyclin C gene, the CYP24 gene and other VDR target genes
demonstrate that equally potent VDR–RXR heterodimer bind-
ing ability can result in completely different 1a,25(OH)2D3
inducibility of the respective gene. Therefore, as an additional
parameter for a prediction of ligand responsiveness the basal
activity of the respective gene’s promoters has to be taken into
account.
The mechanisms of downregulation of genes by
1a,25(OH)2D3 is largely not understood, although microarrays
and other gene expression profiling methods (4,5) suggest that
approximately half of all 1a,25(OH)2D3-responding genes are
downregulated by the hormone. In this respect, the finding that
the protein product of the primary 1a,25(OH)2D3-responding
gene cyclin C is a component of transcriptionally repressive
MED complexes (16), may provide a mechanism to explain
how the downregulation of secondary 1a,25(OH)2D3-
responding genes is mediated. Experiments investigating
this hypothesis are currently underway in our laboratory.
In conclusion, our study provided insight into the regulation
of the cyclin C gene by 1a,25(OH)2D3. We demonstrated that
whole promoter ChIP screening with anti-VDR and anti-RXR
antibodies is suitable for RE identification, found within 8.4 kb
of the cyclin C promoter one strong and three weaker VDREs
and monitored in MCF-7 cells the association of VDR–RXR
with the promoter regions containing these VDREs. This may
help to understand the downregulation of a number of second-
ary 1a,25(OH)2D3-responding genes with an impact on
cellular growth, differentiation and apoptosis.
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